Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


Dr. Soliman on Investigational Combination Therapies in Patients With Breast Cancer

April 30th 2018

Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the use of combination therapies in the treatment of patients with breast cancer.

What Can We Learn From "Extreme Survivors" of Breast Cancer?

April 29th 2018

Mark Burkard, MD, PhD, discusses an unusual study launched at the University of Wisconsin.

Dr. Brufsky on Multiparametric Genomic Assays in Breast Cancer

April 28th 2018

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses multiparametric assays in breast cancer.

Dr. McCloskey on Postoperative Radiation in Patients With Breast Cancer

April 27th 2018

Susan A. McCloskey, MD, MSHS, assistant professor of radiation oncology, University of California Los Angeles (UCLA) Medical Center, Jonsson Comprehensive Cancer Center, discusses the evolution of postoperative radiation in patients with breast cancer.

Expert Encourages Adjuvant Endocrine Therapy in Premenopausal Breast Cancer

April 26th 2018

Reshma L. Mahtani, DO, discusses the use of adjuvant endocrine therapy in premenopausal breast cancers, specifically the use of ovarian function suppression and GnRH agonists.

Dr. Slamon on the Use of Trastuzumab and Bevacizumab Biosimilars in Breast Cancer

April 25th 2018

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the use of biosimilars in clinical practice.

Everolimus Shows Efficacy in Combating Endocrine Resistance in Breast Cancer

April 25th 2018

Everolimus demonstrated strong potential as an effective tool for overcoming endocrine resistance in postmenopausal women with ER-positive, HER2-negative metastatic breast cancer resistant to AI therapy.

Expert Highlights Incorporation of Neoadjuvant Endocrine Therapy Into ER+ Breast Cancer

April 25th 2018

Hung T. Khong, MD, discusses the benefits of neoadjuvant endocrine therapy and addresses the use of adjuvant endocrine therapy in ER-positive breast cancer.

Immunotherapy's Role in TNBC May Be in Combination

April 24th 2018

Hatem Soliman, MD, discusses the potential role of immunotherapy in triple-negative breast cancer.

Dr. Callahan on Endocrine Therapy in Patients With ER-Positive Breast Cancer

April 24th 2018

Rena D. Callahan, MD, assistant clinical professor of medicine, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the use of endocrine therapy in patients with estrogen receptor (ER)-positive breast cancer.

Dr. Master on the Relationship Between Diet and Breast Cancer Recurrence

April 22nd 2018

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the WINS and WHEL trials in patients with breast cancer.

Dr. DiNome on Surgical Approaches in Patients With Breast Cancer

April 22nd 2018

Maggie DiNome, MD, associate professor of surgery, University of California, Los Angeles Medical Center, discusses the evolution of surgical approaches in patients with breast cancer.

Role of PARP Inhibitors in Breast Cancer Continues to Be Refined

April 20th 2018

Nadine M. Tung, MD, discusses the role of PARP inhibitors for patients with BRCA-positive breast cancer and the importance of genetic testing.

Hint of Survival Benefit With Olaparib in HER2-Negative/BRCA-Positive Metastatic Breast Cancer

April 16th 2018

Women with HER2-negative metastatic breast cancer associated with a germline BRCA mutation may have a slight survival advantage with a PARP inhibitor instead of chemotherapy.

Updated Breast Cancer Guidelines Help Evolve Radiation Decisions

April 13th 2018

Laura M. Freedman, MD, discusses the impact of the updated NCCN guidelines on clinical applications of radiation therapy in patients with breast cancer.

Adjuvant Setting in ER-Positive Breast Cancer Undergoing Transformation

April 13th 2018

Ruta D. Rao, MD, elaborates on the findings of the ABCSG-16, SOFT, and TEXT clinical trials and how they have shaped adjuvant treatment for ER-positive breast cancer.

Dr. Blackwell on the Treatment of Young Women With Breast Cancer

April 12th 2018

Kimberly L. Blackwell, MD, medical oncologist, Duke Cancer Institute, discusses the treatment of young women with breast cancer.

Dr. Valdes-Albini on the FDA Approval of Adjuvant Pertuzumab in HER2+ Breast Cancer

April 12th 2018

Frances Valdes-Albini, MD, assistant professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the FDA approval of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Chagpar on Surgery of the Primary Tumor in Metastatic Breast Cancer

April 12th 2018

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses surgery of the primary tumor in the metastatic setting of breast cancer.

Dr. Mamounas on Neoadjuvant Chemotherapy for Breast Cancer

April 12th 2018

Eleftherios (Terry) P. Mamounas, MD, medical director of the Comprehensive Breast Program at the University of Florida Health Cancer Center, discusses the management of neoadjuvant chemotherapy for patients with breast cancer.